CCCC Q4 2020 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$239M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+0.6% YoY

Gross Profit

-$12M-147.3% margin

Operating Income

-$19M-228.8% margin

Net Income

-$22M-263.8% margin

EPS (Diluted)

$-0.53

QoQ Revenue Growth

-2.2%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$400M

Total Liabilities

$119M

Stockholders' Equity

$281M

Cash & Equivalents

$182M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$8M	+0.6%
Gross Profit	-$12M	-$8M	-55.9%
Operating Income	-$19M	-$10M	-80.0%
Net Income	-$22M	-$10M	-117.4%